FDA has become more cautious on drug safety, insiders say

11/14/2010 | Reuters

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX